Sunesis Pharmaceuticals, Inc. (SNSS) Analysts See $-0.29 EPS; Shorts at UCORE RARE METALS COMMON SHARES CA (UURAF) Raised By 167.18%

April 30, 2018 - By Adrian Erickson

Ucore Rare Metals Inc. (OTCMKTS:UURAF) Logo

Analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report $-0.29 EPS on May, 14.They anticipate $0.18 EPS change or 38.30% from last quarter’s $-0.47 EPS. After having $-0.21 EPS previously, Sunesis Pharmaceuticals, Inc.’s analysts see 38.10% EPS growth. The stock increased 0.36% or $0.01 during the last trading session, reaching $2.82. About 30,013 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has declined 37.14% since April 30, 2017 and is downtrending. It has underperformed by 48.69% the S&P500.

UCORE RARE METALS INC COMMON SHARES CA (OTCMKTS:UURAF) had an increase of 167.18% in short interest. UURAF’s SI was 35,000 shares in April as released by FINRA. Its up 167.18% from 13,100 shares previously. With 132,100 avg volume, 0 days are for UCORE RARE METALS INC COMMON SHARES CA (OTCMKTS:UURAF)’s short sellers to cover UURAF’s short positions. The SI to UCORE RARE METALS INC COMMON SHARES CA’s float is 0.02%. The stock increased 1.82% or $0.003 during the last trading session, reaching $0.168. About 13,595 shares traded. Ucore Rare Metals Inc. (OTCMKTS:UURAF) has 0.00% since April 30, 2017 and is . It has underperformed by 11.55% the S&P500.

Ucore Rare Metals Inc., a junior exploration company, engages in the exploration of rare earth elements in Canada and the United States. The company has market cap of $46.09 million. It primarily holds a 100% interest in the Bokan Mountain/Dotson Ridge property located on Prince of Wales Island, Alaska. It currently has negative earnings. The firm was formerly known as Ucore Uranium Inc. and changed its name to Ucore Rare Metals Inc. in June 2010.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $96.93 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was upgraded by Wells Fargo on Monday, December 11 to “Buy”. The stock has “Hold” rating by Cantor Fitzgerald on Friday, July 24. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Buy” rating given on Monday, November 20 by Oppenheimer. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) earned “Outperform” rating by Wells Fargo on Friday, July 29. On Thursday, December 14 the stock rating was initiated by Oppenheimer with “Buy”. Wells Fargo downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Tuesday, December 5 to “Market Perform” rating. TH Capital downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Friday, July 24 to “Sell” rating. Cowen & Co downgraded the shares of SNSS in report on Friday, July 24 to “Market Perform” rating. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, July 27. Cantor Fitzgerald maintained Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rating on Tuesday, July 18. Cantor Fitzgerald has “Hold” rating and $300 target.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>